EP3326637B1 - Use of mangosteen rind extract in preparation of medicine for treating skin diseases - Google Patents
Use of mangosteen rind extract in preparation of medicine for treating skin diseases Download PDFInfo
- Publication number
- EP3326637B1 EP3326637B1 EP16829794.3A EP16829794A EP3326637B1 EP 3326637 B1 EP3326637 B1 EP 3326637B1 EP 16829794 A EP16829794 A EP 16829794A EP 3326637 B1 EP3326637 B1 EP 3326637B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mangosteen
- rind
- composition
- extract
- paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006053 Garcinia mangostana Species 0.000 title claims description 100
- 235000017048 Garcinia mangostana Nutrition 0.000 title claims description 99
- 241000283690 Bos taurus Species 0.000 title claims description 89
- 238000002360 preparation method Methods 0.000 title claims description 20
- 208000017520 skin disease Diseases 0.000 title description 17
- 239000003814 drug Substances 0.000 title description 15
- 239000000203 mixture Substances 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 22
- 201000008937 atopic dermatitis Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- -1 /or Species 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- VEZXFTKZUMARDU-UHFFFAOYSA-N gamma-mangostin Chemical compound OC1=C(O)C(CC=C(C)C)=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 VEZXFTKZUMARDU-UHFFFAOYSA-N 0.000 claims description 10
- 102000003812 Interleukin-15 Human genes 0.000 claims description 8
- 108090000172 Interleukin-15 Proteins 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 7
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 claims description 5
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 claims description 5
- ZVFQDLCERPGZMO-UHFFFAOYSA-N alpha-mangostin Natural products OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3CC2=C1 ZVFQDLCERPGZMO-UHFFFAOYSA-N 0.000 claims description 5
- ACRGTLGOYYTGNX-UHFFFAOYSA-N gamma-mangostin Natural products OC1=C(O)C=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 ACRGTLGOYYTGNX-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000010668 atopic eczema Diseases 0.000 description 13
- 208000027866 inflammatory disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 9
- 210000005069 ears Anatomy 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 8
- 230000000172 allergic effect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229960001067 hydrocortisone acetate Drugs 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 235000001497 healthy food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- YRKKJHJIWCRNCW-UHFFFAOYSA-N beta-Mangostin Chemical compound O1C2=CC(O)=C(OC)C(CC=C(C)C)=C2C(=O)C2=C1C=C(OC)C(CC=C(C)C)=C2O YRKKJHJIWCRNCW-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 201000008298 histiocytosis Diseases 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 208000011379 keloid formation Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UHGGERUQGSJHKR-VCDGYCQFSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;octadecanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCCCCCCCC(O)=O UHGGERUQGSJHKR-VCDGYCQFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101000845012 Macrovipera lebetina Disintegrin lebein-1-alpha Proteins 0.000 description 1
- 101000845007 Macrovipera lebetina Disintegrin lebein-1-beta Proteins 0.000 description 1
- 208000035268 Mast Cell Activation disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 206010058141 Skin graft rejection Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940124384 agent for atopic dermatitis Drugs 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- ZZNMWGVMOBOREI-VQTJNVASSA-N chembl464952 Chemical compound C1([C@H]2OC=3C4=C(C=5C=CC(C)(C)OC=5C=3C(=O)[C@@H]2O)OC(C=C4)(C)C)=CC=CC=C1 ZZNMWGVMOBOREI-VQTJNVASSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000013256 infectious meningitis Diseases 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- RYZCLUQMCYZBJQ-UHFFFAOYSA-H lead(2+);dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Pb+2].[Pb+2].[Pb+2].[O-]C([O-])=O.[O-]C([O-])=O RYZCLUQMCYZBJQ-UHFFFAOYSA-H 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to a composition for use in the treatment of skin diseases.
- Skin is the largest organ of the human body.
- Skin diseases may be acute (lasting only a few minutes to several hours) or chronic conditions, which may affect individuals for days, months, years and even the entire life.
- Skin diseases may be conditions caused by fungal, bacterial, or viral sources, or may be non-infectious, immune responses, such as inflammatory reactions with or without allergens, or idiopathic. Therefore, the symptoms of the skin diseases may vary and range from mild itching, redness and swelling to severe pus and nociceptive pain, for examples damaging ulceration. Skin diseases may impose significant impact on the quality of an individual's life.
- Skin diseases may be ulosis, dermatitis, proliferative diseases or conditions, mast cell diseases or conditions, burns, contact with allergens and/or irritants, or inflammatory diseases or conditions, skin diseases including atopic dermatitis, bullous dermatosis, collagenous diseases, psoriasis, psoriatic lesions, contact dermatitis, eczema, urticaria, rosacea, hypertrophic scarring, keloid formation, scleroderma, folliculitis, burns or mucin histiocytosis.
- Atopic dermatitis also known as atopic eczema
- atopic eczema is a recurrent allergic skin disease, often associated with genetic disorders, is one of the most common skin diseases in infants and toddlers, accounting for about 3 to 5% of the pediatric population, 60% of these patients develop disease within one year of age, while 30% of patients develop disease between the ages of 1 and 5 years.
- About half of children suffering from atopic dermatitis also develop allergic rhinitis, asthma, allergic conjunctivitis, etc., also known as allergic children, or known as atopic predisposition.
- Psoriasis is a common chronic skin disease, also known as white crust. It is characterized by the appearance of papules, erythema, the surface covered with silver-white scales, clear boundaries, often recurring in scalp, extensor limbs and back.
- Folliculitis is suppurative inflammation caused by fungal invasion of follicular parts, which often occurs in heads, necks, buttocks, genitals, perianal areas or other parts of the body, and prone to relapse.
- Contact dermatitis is an inflammatory reaction caused by exposure of skin mucosa to external substances, such as chemical fiber clothing, cosmetics, drugs, etc. Its clinical features are sharp-edge-damages to contacted areas, patients with mild conditions suffer from edematous erythema, papules, patients with severe conditions suffer from Molluscum contagiosum (water warts) or even big scars, patients with more serious conditions suffer from epidermolysis, or even necrosis.
- the usual ways of treating skin diseases include oral or external formulations.
- Steroid and antihistamine drugs are now widely used to treat allergic diseases of atopic dermatitis, in severe cases, immunosuppressive agents may be given.
- these formulations or drugs only show short-term therapeutic effects and are prone to adverse side effects such as skin atrophy, skin depigmentation, acne, osteoporosis, avascular necrosis, arteriosclerosis, glaucoma, enhanced tumor growth, etc. Therefore, there is an urgent need to develop a novel therapeutic agent which may be used for symptom relief and treatment of atopic dermatitis and is able to provide powerful and long-lasting therapeutic effects with reduced side effects.
- Mangosteen has been used in the field of breast cancer prevention and muscle-related diseases, it has also been developed as nutritional supplements and cosmetics in daily lives, as well as uses in the treatment of acute hepatitis, liver fibrosis and cirrhosis prevention (ROC Patent No. 1411432 ).
- Matsumoto et al. have studied ⁇ -mangostin, ⁇ -mangostin, ⁇ - mangostin, and methyl- ⁇ -mangostin purified from mangosteen rinds and investigated the inhibitory effect of this compound at various stages of the cell cycle, showing that this compound has anti-cell proliferative effect and anti-tumor effect ( Bioorg. Med. Chem. 2005, 13, 6064-6069 ).
- Patent application publication EP 2415476 A1 discloses that a mangosteen extract effects treatment or prevention of atopic dermatitis by its oral ingestion.
- Patent application publication US 2006/105069 A1 describes that the extract of mangosteen rind can be used for treating skin diseases.
- the present invention provides a composition for use in the treatment of atopic dermatitis according to claim 1. Further embodiments are subject-matter of the dependent claims.
- compositions for use in the treatment of autoimmune diseases or allergies wherein the composition comprises an effective amount of extract of mangosteen rind.
- the drug may also be used for topical treatment or for precision treatment.
- the mangosteen rind may be extracted with a solvent which is selected from the group consisting of methanol, ethanol, n-propanol, 2-propanol, n-butanol, acetone, ethyl acetate and water.
- the extract of mangosteen rind is water extract of mangosteen rind and/or alcohol extract of mangosteen rind.
- the extract of mangosteen rind is a mangosteen rind water extract; in another example, the extract of mangosteen rind is mangosteen rind alcohol extract.
- Mangosteen rind refers to the portion of the mangosteen that is outside the fresh, the rind contains a softer inner rind and a harder outer rind.
- the mangosteen rind is the outer rind of the mangosteen rind and/or the inner rind of the mangosteen rind.
- the mangosteen rind is the outer rind of the mangosteen rind.
- the composition further comprises an excipient, wherein the ratio of the excipient is 1% to 10% and the composition still maintains its therapeutic efficacy.
- the water extract of mangosteen rind can stop itching and/or promote cell proliferation.
- the mangosteen rind alcohol extract is anti-inflammatory and/or analgesic.
- the mangosteen rind extract is capable of inhibiting an increase of the immunomodulatory hormone IL-7, IL-10, but not the pro-inflammatory cytokine IL-1 or TNF- ⁇ .
- the mangosteen outer rind extract mainly inhibits an increase of IL-7 and IL-10, and also inhibits an increase of IL-15 and MCP-1;
- the mangosteen inner rind extract mainly inhibits an increase of IL-7, IL-10, IL-15, it also inhibits an increase of MCP-1.
- composition disclosed herein may further comprise an oil.
- compositions disclosed herein may be oral or parenteral preparations.
- compositions are parenteral preparations.
- the parenteral preparations may be external preparations which may be creams, pastes, ointments, gels, wash lotions or patches.
- the extract of mangosteen rind of the present invention comprises ⁇ -mangostin and ⁇ -mangostin.
- the water extract of mangosteen rind comprises ⁇ -mangostin and ⁇ -mangostin.
- the alcohol extract of mangosteen rind comprises ⁇ -mangostin and ⁇ -mangostin.
- composition of the present invention can be used to treat or suppress atopic dermatitis by inhibiting immunomodulatory hormones and not by inhibiting inflammatory cytokines such as IL-1 or TNF ⁇ , etc.
- Skin diseases include atopic dermatitis, bullous dermatosis, collagenous diseases, psoriasis, psoriatic lesions, contact dermatitis, eczema, urticaria, rosacea, hypertrophic scarring, keloid formation, scleroderma, folliculitis, burns or mucin histiocytosis.
- allergic disorder refers to a disease, symptom, or condition that is caused by being allergic to non-hazardous substances.
- substances may be present in the environment (e.g., indoor air pollutants and airborne allergens) or not originated from the environment (e.g., those substances that cause skin or food allergies). Allergens can enter the body through many routes, including through breathing, ingestion, skin contact or injection (including insect bites).
- Many allergic conditions are associated with atopic predisposition to produce IgE antibodies. Because IgE sensitizes mast cells anywhere in the body, individuals with atopic predisposition often manifest the disease in more than one organs.
- an allergic disorder includes any allergic reactions that occurs when re-exposed to a sensitizing allergen, which in turn results in the release of inflammation mediators.
- Allergic disorders include allergic rhinitis (e.g., hay fever), sinusitis, rhinosinusitis, chronic or recurrent otitis media, drug reactions, reactions to insect bites, reactions to latex, conjunctivitis, urticaria, generalized allergic reaction (anaphylaxis) and anaphylactoid reaction, atopic dermatitis, asthma and food allergies.
- an extract disclosed herein can be used in the prevention or treatment of an inflammatory disorder.
- inflammatory disorder refers to a disease, a disorder, or a condition characterized by inflammation of the body tissue or having an inflammatory component. It includes local inflammatory reaction and systemic inflammation.
- inflammatory disorders include: transplant rejection, including skin graft rejection; chronic inflammatory disorders of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and skeletal disorders associated with increased bone loss; inflammatory intestinal diseases such as ileitis, ulcerative colitis, Barrett's syndrome and Crohn's disease; inflammatory lung disorders such as asthma, adult respiratory distress syndrome and chronic obstructive pulmonary disease; ocular inflammatory disorders including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic gingival inflammation disorders including gingivitis and periodontitis; tuberculosis; leprosy; kidney inflammatory diseases, including uremic complications, glomerulonephritis and nephropathy; skin inflammatory disorders, including sclerodermatitis, psoriasis and eczema; central nervous system inflammatory diseases including chronic demyelinating disorders of the nervous system, multiple sclerosis
- inflammation there may also be generalized inflammation such as Gram-positive or Gram-negative shock, hemorrhagic or anaphylactic shock, or shocks induced by chemotherapy due to reactions to inflammatory cytokines, such as shocks associated with inflammatory cytokines.
- This shock can be induced, for example, by chemotherapeutic agents used in cancer chemotherapy.
- treatment of inflammatory disorders refers to the administration of a compound or composition disclosed herein to a subject suffering from, or having symptoms of, or likely to suffer from an inflammatory disorder, in order to treat, alleviate, alter, affect or prevent the inflammatory disorder, symptoms or development thereof.
- Effective amount is the amount that can achieve effective results when administered to an individual, or that has the desired activity in vivo or in vitro.
- effective clinical outcomes include amelioration of the extent or severity of the symptoms associated with the disease or condition, and/or prolonging the life of an individual and/or improvement of the quality of life of the individual.
- the exact amount of compound administered to an individual will depend on the type and severity of the disease or symptoms and on the individual characteristics such as the general health of the individual, age, sex, weight, and drug tolerance of the individual. It is also dictated by the conditions, severity and types of the inflammatory disorder, the autoimmune disorder and the allergic disorder, or the desired immunosuppressive effect. Those skilled in the art will be able to determine the appropriate dose based on these and other factors.
- the effective amount of extract of mangosteen rind is 20 mg/kg to 200 mg/kg.
- the present disclosure relates to an extract or a pharmaceutical composition that are particularly useful in immunosuppression or in the treatment or prevention of inflammation, immune disorders and allergic disorders.
- compositions of the present disclosure may be formulated into various forms of oral or parenteral preparations.
- Oral preparations may be formulated as solid preparations such as powders, granules, troches, capsules, etc., or formulated as liquid preparations such as suspensions, emulsions, syrups, etc.
- Parenteral preparations may be formulated as external preparations such as creams, ointments, gels, wash lotions, patches, etc, or as inhalants, aerosols, suppositories, etc.
- the pharmaceutical composition may comprise pharmaceutically acceptable excipients, especially may further comprise predetermined solvents or oils, and if desired, may further comprise a dispersant.
- solvents examples include water, ethanol, isopropanol, 1,3-butanediol, propylene glycol, glycerin, etc.
- oils that can be used in the present disclosure are selected from the group consisting of corn oil, sesame oil, flaxseed oil, cottonseed oil, soybean oil, peanut oil, mono-glycerides, diglycerides, tri-glycerides, mineral oil, squalene, jojoba oil, olive oil, evening primrose oil, borage oil, grape seed oil, coconut oil, sunflower oil, shea butter, and any combinations thereof.
- Solvents and oils may be used alone or in any combinations thereof.
- useful dispersants may include lecithin, organic monoglycerides, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan stearate, etc. These raw materials may also be used alone or in any combinations thereof.
- composition may further comprise additional materials, such as antimicrobials or preservatives.
- ceramide moisturizers are commonly used as conventional agents for atopic dermatitis, or liquid ingredients such as hydrocortisone steroids, vitamin A derivatives such as vitamin A palmitate and/or tocopherol, etc. may be used with the composition.
- an appropriate external skin preparation may be used as a base material, and an aqueous solution, a non-aqueous solvent, a suspension, an emulsion or a lyophilized preparation, etc., may be used and sterilized according to known methods.
- the dosage may be determined depending on various factors such as the route of administration, the age, sex, and weight of the patient, the severity of the disease, and the type of medicament as the active ingredient.
- the composition may be a food or a cosmetic composition
- the composition may be prepared by appropriate addition of at least one food supplement or a cosmetically acceptable carrier.
- the food composition can be used in or added to, for example, healthy foods.
- healthy foods refers to a food product containing the composition of the present disclosure that has an enhanced function as compared to general food products. Healthy foods can be prepared by adding a general food to the composition or by encapsulation, pulverization or suspension liquefaction.
- the cosmetic composition may be added alone or together with other cosmetic ingredients, or may be appropriately used according to other known methods.
- Cosmetics include aftershaves, lotions, creams, facial masks and color makeups.
- Cosmetic compositions can be formulated into various forms of compositions, such as gels, creams, ointments, etc.
- the compositions in the form of gels, creams and ointments may be appropriately prepared according to the form of the composition by using known methods, and by addition of known softeners, emulsifiers and thickeners or other materials known in the art.
- the gel-form composition can be prepared, for example, by addition of a softener such as trimethylolpropane, polyethylene glycol and glycerol, for example, a solvent of propylene glycol, ethanol and isocetyl alcohol, and pure water.
- a softener such as trimethylolpropane, polyethylene glycol and glycerol
- a solvent of propylene glycol, ethanol and isocetyl alcohol for example, a solvent of propylene glycol, ethanol and isocetyl alcohol, and pure water.
- compositions in the form of creams can be carried out, for example, by addition of fatty alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, resveratrol, isostearyl alcohol and isocetyl alcohol; emulsifiers such as lipids, such as lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidyl serine, phosphoinositide and derivatives thereof, glyceryl stearate, sorbitol palmitate, sorbitol stearate, etc; natural fats and oils such as avocado oil, almond oil, babassu oil, borage oil, camellia oil, etc; lipid compositions such as ceramides, cholesterol, fatty acids, phytosphingosine, lecithin, etc; solvents, such as propylene glycol, etc; and pure water.
- fatty alcohols such as stearyl alcohol, myristyl alcohol, beheny
- compositions in the form of ointments can be carried out, for example, by addition of emollients, emulsifiers and waxes, for example microcrystalline wax, paraffin, ceresin, beeswax, spermaceti, petrolatum, etc.
- emollients for example microcrystalline wax, paraffin, ceresin, beeswax, spermaceti, petrolatum, etc.
- composition disclosed herein may be used to prepare a medicament for treating or alleviating atopic dermatitis.
- treating or alleviating means that when a patient uses a medicament, it stops or delays the course or symptoms of the disease.
- Mangosteen rind was collected and dried to 50% to 95%, extracted with a solvent (such as water or 10% to 95% alcohol), and concentrated to obtain an extract of mangosteen rind.
- a solvent such as water or 10% to 95% alcohol
- the outer rind and inner rind of the mangosteen rind were separated, the outer rind of the mangosteen rind and the inner rind of the mangosteen rind were respectively dried to 50% to 95%, and extracted with a solvent (such as water or 10% to 95% alcohol), then concentrated to obtain an extract of mangosteen outer rind and an extract of mangosteen inner rind.
- a solvent such as water or 10% to 95% alcohol
- mice 8-week-old BALB/c mice (purchased from LESCO Biotech), the body weight were 25 to 28 g and were quarantined by veterinarians for one week before entering the breeding room.
- the animals were divided into 9 groups, 3 in each group, a total of 27 mices.
- the temperature of the breeding room was set at 21 ⁇ 2 °C, the humidity was set at 30 to 70%, and the environment was set for 12/12 hour light-dark cycle with unlimited supply of food and water.
- TNCB 2-chloro-1,3,5-trinitrobezene
- acetone was used as the solvent to prepare 1% of TNCB which was applied to mice ears (once every 2 days, the volume was 4 ml/kg) one week prior to testings.
- the test substance once per day was started after one week, the given volume was 4 ml/kg, and the mice were continuously induced with TNCB (once every 2 days).
- the oral dose was 60 mg/kg and the volume was 10 ml/kg.
- TNCB and the test substance were given on the same day, in order to reduce the effect of interactions between each other, TNCB and test substance were given at least 1 hour apart.
- the designed experimental groups are shown in the following table.
- the mangosteen paste of 0.5%, 1%, 2%, 3%, 5% respectively contained 20 mg/kg, 40 mg/kg, 80 mg/kg, 120 mg/kg and 200 mg/kg of extract of mangosteen rind. Table 1.
- mice Changes in body weight and ear thickness of the mice were monitored twice weekly. Blood of all experimental animals were collected before TNCB induction, after the induction and before the test substance was given and when being sacrificed. After the blood was centrifuged at 3000 rpm for 30 minutes at 4 °C, serum samples were obtained and stored.
- mice All animals were sacrificed at the end of the third week after the test substance was given. Mice ears were removed, photographed and stored in 10% of formalin solution for histopathological observation. HE staining was used for the pathological observation (conducted by the National Laboratory Animal Center).
- Body weight After the formation of atopic dermatitis was induced by TNCB in the mice and one week after the test substance was given to the mice, only slight weight loss as a result of discomfort was observed and there was no statistically significant difference in body weight ( Figure 1 ).
- mice ears were removed after the experiment and weighed. It was observed that as the dose of the test substance increased, the weight of the mice ears gradually decreased. The inhibition rate of 82.4% and 69.5% (p ⁇ 0.01) were respectively observed in the groups that received a positive control group drug (1% hydrocortisone acetate) and a high dose of test substance (5%) as compared with the model group. In addition, the inhibition rate of 28.2% and 28.9% were respectively observed in 2% and 3% of the test substances (p ⁇ 0.05) (Table 2, Figure 3 ).
- Ear appearance after being sacrificed Mice ears were removed for observation of the appearance at the end of 1 experiment, an intact ear contour was found in the group that received a positive control group drug (1% hydrocortisone acetate) and in the group that received a high dose (5%), less surface furfures and roughness were also observed ( Figure 4 ).
- TNCB-induced chronic-active dermatitis The severity of TNCB-induced chronic-active dermatitis was divided into five levels according to the results of the pathological analysis conducted by the National Laboratory Animal Center: minimal (Grade 1), mild (Grade 2), moderate (Grade 3), moderately severe (Grade 4), and extremely severe (Grade 5).
- Mangosteen inner rind and outer ring extract analysis According to the results of pathological slices conducted by the National Laboratory Animal Center, the severity of TNCB-induced chronic-active dermatitis was divided into five levels: minimal (Grade 1), mild (Grade 2), moderate (Grade 3), moderately Severe (Grade 4), and extremely severe (Grade 5). The results showed that the outer rind had an effect better than the inner rind (Table 4). Table 4. Ear thickness and ear weight inhibition rate (%) of experimental groups Inhibition rate (%) 1% Hydrocortisone Acetate Mangosteen outer rind (4%) Mangosteen inner rind (4%) Ear weight 68.91 54.62 36.047 Ear thickness 50.75 40.04 24.84
- Serum was retained when the mice were sacrificed, and biochemical markers (IL-1 ⁇ , IL-2, IL-4, IL-3, IL-5, IL-7, IL-10, IL-12 (p40), IL-15, IL-17, MCP-1, RANTES, TNF- ⁇ ) in the serum were analyzed by using the MAGPIX System (Millipore, USA) and the MCYTOMAG Assay Kit (Millipore, USA).
- biochemical markers IL-1 ⁇ , IL-2, IL-4, IL-3, IL-5, IL-7, IL-10, IL-12 (p40), IL-15, IL-17, MCP-1, RANTES, TNF- ⁇
- mangosteen outer rind extract Similar to the mode of action of steroid drugs, a part of the immune system could be suppressed, which in turns affected atopic dermatitis.
- the mangosteen outer rind extract which completely inhibited IL-10, was significantly superior to the inner rind extract, and IL-10 was an important cytokine formed by the T H 2 pathway antibodies. Therefore, mangosteen outer rind extract imposed more significant effects on atopic dermatitis than the mangosteen inner rind extract did.
- the mode of action of mangosteen rind was similar to that of a steroid drug, with regard to IL-15, the steroids were able to inhibit the production of IL-15, but the mangosteen outer rind had more significant effect.
- composition of the present invention had a significant effect on atopic dermatitis.
- Example 4 High performance liquid chromatography analysis of alcohol extract of mangosteen rind
- the chemical fingerprints spectrum of the alcohol extract of mangosteen rind was analyzed by using a high performance liquid chromatography (HPLC). 300 mg ⁇ 1 mg of alcohol extract of mangosteen rind was weighed and placed in a 100 mL volumetric flask and diluted to 100 mL with a diluent, which was shaked by ultrasonic waves for at least 60 min until completely dissolved, allowed to stand at room temperature.
- HPLC high performance liquid chromatography
- HPLC high performance liquid chromatography
- COSMOSIL MS-II 5um, 4.6 x 250 mm, Waters
- a 10 L sample was introduced into the HPLC system.
- Figure 6 shows the HPLC chemical fingerprint spectrum analysis of the alcohol extract of mangosteen rind. The results showed that the alcohol extract of mangosteen rind had HPLC peaks with the following retention times (Table 6). Table 6. HPLC spectrum wave peaks of alcohol extract of mangosteen rind Number of wave peaks Retention time (minute) 1 5.53 2 6.22 3 12.48 4 14.24 5 16.29 6 20.04 7 24.41
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- The present invention relates to a composition for use in the treatment of skin diseases.
- Skin is the largest organ of the human body. There are many types of skin diseases. Skin diseases may be acute (lasting only a few minutes to several hours) or chronic conditions, which may affect individuals for days, months, years and even the entire life. Skin diseases may be conditions caused by fungal, bacterial, or viral sources, or may be non-infectious, immune responses, such as inflammatory reactions with or without allergens, or idiopathic. Therefore, the symptoms of the skin diseases may vary and range from mild itching, redness and swelling to severe pus and nociceptive pain, for examples damaging ulceration. Skin diseases may impose significant impact on the quality of an individual's life.
- Skin diseases may be ulosis, dermatitis, proliferative diseases or conditions, mast cell diseases or conditions, burns, contact with allergens and/or irritants, or inflammatory diseases or conditions, skin diseases including atopic dermatitis, bullous dermatosis, collagenous diseases, psoriasis, psoriatic lesions, contact dermatitis, eczema, urticaria, rosacea, hypertrophic scarring, keloid formation, scleroderma, folliculitis, burns or mucin histiocytosis.
- Atopic dermatitis, also known as atopic eczema, is a recurrent allergic skin disease, often associated with genetic disorders, is one of the most common skin diseases in infants and toddlers, accounting for about 3 to 5% of the pediatric population, 60% of these patients develop disease within one year of age, while 30% of patients develop disease between the ages of 1 and 5 years. About half of children suffering from atopic dermatitis also develop allergic rhinitis, asthma, allergic conjunctivitis, etc., also known as allergic children, or known as atopic predisposition.
- Psoriasis is a common chronic skin disease, also known as white crust. It is characterized by the appearance of papules, erythema, the surface covered with silver-white scales, clear boundaries, often recurring in scalp, extensor limbs and back.
- Folliculitis is suppurative inflammation caused by fungal invasion of follicular parts, which often occurs in heads, necks, buttocks, genitals, perianal areas or other parts of the body, and prone to relapse.
- Contact dermatitis is an inflammatory reaction caused by exposure of skin mucosa to external substances, such as chemical fiber clothing, cosmetics, drugs, etc. Its clinical features are sharp-edge-damages to contacted areas, patients with mild conditions suffer from edematous erythema, papules, patients with severe conditions suffer from Molluscum contagiosum (water warts) or even big scars, patients with more serious conditions suffer from epidermolysis, or even necrosis.
- The usual ways of treating skin diseases include oral or external formulations. Steroid and antihistamine drugs are now widely used to treat allergic diseases of atopic dermatitis, in severe cases, immunosuppressive agents may be given. However, these formulations or drugs only show short-term therapeutic effects and are prone to adverse side effects such as skin atrophy, skin depigmentation, acne, osteoporosis, avascular necrosis, arteriosclerosis, glaucoma, enhanced tumor growth, etc. Therefore, there is an urgent need to develop a novel therapeutic agent which may be used for symptom relief and treatment of atopic dermatitis and is able to provide powerful and long-lasting therapeutic effects with reduced side effects.
- Mangosteen has been used in the field of breast cancer prevention and muscle-related diseases, it has also been developed as nutritional supplements and cosmetics in daily lives, as well as uses in the treatment of acute hepatitis, liver fibrosis and cirrhosis prevention (ROC Patent No.
1411432 - Matsumoto et al. have studied α-mangostin, β-mangostin, γ- mangostin, and methyl-β-mangostin purified from mangosteen rinds and investigated the inhibitory effect of this compound at various stages of the cell cycle, showing that this compound has anti-cell proliferative effect and anti-tumor effect (Bioorg. Med. Chem. 2005, 13, 6064-6069).
- From patent application publication
WO 2007/002666 A2 it is known to use the rind, leaves and bark of the mangosteen plant as ingredients in folk medicine for treating eczema. - Patent application publication
EP 2415476 A1 discloses that a mangosteen extract effects treatment or prevention of atopic dermatitis by its oral ingestion. - Patent application publication
US 2006/105069 A1 describes that the extract of mangosteen rind can be used for treating skin diseases. - The present invention provides a composition for use in the treatment of atopic dermatitis according to
claim 1. Further embodiments are subject-matter of the dependent claims. - Further disclosed herein is a composition for use in the treatment of autoimmune diseases or allergies, wherein the composition comprises an effective amount of extract of mangosteen rind. The drug may also be used for topical treatment or for precision treatment.
- According to the present disclosure, the mangosteen rind may be extracted with a solvent which is selected from the group consisting of methanol, ethanol, n-propanol, 2-propanol, n-butanol, acetone, ethyl acetate and water.
- In a embodiment, the extract of mangosteen rind is water extract of mangosteen rind and/or alcohol extract of mangosteen rind. In one example, the extract of mangosteen rind is a mangosteen rind water extract; in another example, the extract of mangosteen rind is mangosteen rind alcohol extract.
- Mangosteen rind refers to the portion of the mangosteen that is outside the fresh, the rind contains a softer inner rind and a harder outer rind.
- In a preferred embodiment, the mangosteen rind is the outer rind of the mangosteen rind and/or the inner rind of the mangosteen rind.
- In another preferred embodiment, the mangosteen rind is the outer rind of the mangosteen rind.
- In a preferred embodiment, the composition further comprises an excipient, wherein the ratio of the excipient is 1% to 10% and the composition still maintains its therapeutic efficacy.
- According to the present disclosure, the water extract of mangosteen rind can stop itching and/or promote cell proliferation. According to the present disclosure, the mangosteen rind alcohol extract is anti-inflammatory and/or analgesic.
- In yet another preferred embodiment, the mangosteen rind extract is capable of inhibiting an increase of the immunomodulatory hormone IL-7, IL-10, but not the pro-inflammatory cytokine IL-1 or TNF-α. The mangosteen outer rind extract mainly inhibits an increase of IL-7 and IL-10, and also inhibits an increase of IL-15 and MCP-1; the mangosteen inner rind extract mainly inhibits an increase of IL-7, IL-10, IL-15, it also inhibits an increase of MCP-1.
- The composition disclosed herein may further comprise an oil.
- In general, the compositions disclosed herein may be oral or parenteral preparations. However, according to the present invention, the compositions are parenteral preparations. The parenteral preparations may be external preparations which may be creams, pastes, ointments, gels, wash lotions or patches.
- In a preferred embodiment, the extract of mangosteen rind of the present invention comprises α-mangostin and γ-mangostin.
- In one example disclosed herein, the water extract of mangosteen rind comprises α-mangostin and γ-mangostin.
- In yet another example disclosed herein, the alcohol extract of mangosteen rind comprises α-mangostin and γ-mangostin.
- The composition of the present invention can be used to treat or suppress atopic dermatitis by inhibiting immunomodulatory hormones and not by inhibiting inflammatory cytokines such as IL-1 or TNFα, etc.
- Skin diseases include atopic dermatitis, bullous dermatosis, collagenous diseases, psoriasis, psoriatic lesions, contact dermatitis, eczema, urticaria, rosacea, hypertrophic scarring, keloid formation, scleroderma, folliculitis, burns or mucin histiocytosis.
- As used herein, the term "allergic disorder" refers to a disease, symptom, or condition that is caused by being allergic to non-hazardous substances. Such substances may be present in the environment (e.g., indoor air pollutants and airborne allergens) or not originated from the environment (e.g., those substances that cause skin or food allergies). Allergens can enter the body through many routes, including through breathing, ingestion, skin contact or injection (including insect bites). Many allergic conditions are associated with atopic predisposition to produce IgE antibodies. Because IgE sensitizes mast cells anywhere in the body, individuals with atopic predisposition often manifest the disease in more than one organs. For purposes of the present disclosure, an allergic disorder includes any allergic reactions that occurs when re-exposed to a sensitizing allergen, which in turn results in the release of inflammation mediators. Allergic disorders include allergic rhinitis (e.g., hay fever), sinusitis, rhinosinusitis, chronic or recurrent otitis media, drug reactions, reactions to insect bites, reactions to latex, conjunctivitis, urticaria, generalized allergic reaction (anaphylaxis) and anaphylactoid reaction, atopic dermatitis, asthma and food allergies.
- An extract disclosed herein can be used in the prevention or treatment of an inflammatory disorder. As used herein, the term "inflammatory disorder" refers to a disease, a disorder, or a condition characterized by inflammation of the body tissue or having an inflammatory component. It includes local inflammatory reaction and systemic inflammation. Examples of such inflammatory disorders include: transplant rejection, including skin graft rejection; chronic inflammatory disorders of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and skeletal disorders associated with increased bone loss; inflammatory intestinal diseases such as ileitis, ulcerative colitis, Barrett's syndrome and Crohn's disease; inflammatory lung disorders such as asthma, adult respiratory distress syndrome and chronic obstructive pulmonary disease; ocular inflammatory disorders including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic gingival inflammation disorders including gingivitis and periodontitis; tuberculosis; leprosy; kidney inflammatory diseases, including uremic complications, glomerulonephritis and nephropathy; skin inflammatory disorders, including sclerodermatitis, psoriasis and eczema; central nervous system inflammatory diseases including chronic demyelinating disorders of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis, and viral or autoimmune encephalitis; autoimmune disorders, immune complex vasculitis, systemic lupus and erythema; systemic lupus erythematosus (SLE); and cardiac inflammatory diseases such as cardiomyopathy, ischemic heart disease (hypercholesterolemia, atherosclerosis); as well as various other diseases with significant inflammatory components including preeclampsia, chronic liver failure, brain and spinal cord injury, cancer. There may also be generalized inflammation such as Gram-positive or Gram-negative shock, hemorrhagic or anaphylactic shock, or shocks induced by chemotherapy due to reactions to inflammatory cytokines, such as shocks associated with inflammatory cytokines. This shock can be induced, for example, by chemotherapeutic agents used in cancer chemotherapy. As used herein, "treatment of inflammatory disorders" refers to the administration of a compound or composition disclosed herein to a subject suffering from, or having symptoms of, or likely to suffer from an inflammatory disorder, in order to treat, alleviate, alter, affect or prevent the inflammatory disorder, symptoms or development thereof.
- "Effective amount" is the amount that can achieve effective results when administered to an individual, or that has the desired activity in vivo or in vitro. In the case of inflammatory disorders and autoimmune disorders, as compared to no treatment, effective clinical outcomes include amelioration of the extent or severity of the symptoms associated with the disease or condition, and/or prolonging the life of an individual and/or improvement of the quality of life of the individual. The exact amount of compound administered to an individual will depend on the type and severity of the disease or symptoms and on the individual characteristics such as the general health of the individual, age, sex, weight, and drug tolerance of the individual. It is also dictated by the conditions, severity and types of the inflammatory disorder, the autoimmune disorder and the allergic disorder, or the desired immunosuppressive effect. Those skilled in the art will be able to determine the appropriate dose based on these and other factors.
- In a preferred embodiment, the effective amount of extract of mangosteen rind is 20 mg/kg to 200 mg/kg.
- The present disclosure relates to an extract or a pharmaceutical composition that are particularly useful in immunosuppression or in the treatment or prevention of inflammation, immune disorders and allergic disorders.
- The pharmaceutical composition of the present disclosure may be formulated into various forms of oral or parenteral preparations. Oral preparations may be formulated as solid preparations such as powders, granules, troches, capsules, etc., or formulated as liquid preparations such as suspensions, emulsions, syrups, etc. Parenteral preparations may be formulated as external preparations such as creams, ointments, gels, wash lotions, patches, etc, or as inhalants, aerosols, suppositories, etc.
- The pharmaceutical composition may comprise pharmaceutically acceptable excipients, especially may further comprise predetermined solvents or oils, and if desired, may further comprise a dispersant.
- Examples of solvents that may be used in the present disclosure include water, ethanol, isopropanol, 1,3-butanediol, propylene glycol, glycerin, etc.
- Examples of oils that can be used in the present disclosure are selected from the group consisting of corn oil, sesame oil, flaxseed oil, cottonseed oil, soybean oil, peanut oil, mono-glycerides, diglycerides, tri-glycerides, mineral oil, squalene, jojoba oil, olive oil, evening primrose oil, borage oil, grape seed oil, coconut oil, sunflower oil, shea butter, and any combinations thereof.
- Solvents and oils may be used alone or in any combinations thereof.
- Examples of useful dispersants may include lecithin, organic monoglycerides, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan stearate, etc. These raw materials may also be used alone or in any combinations thereof.
- If desired, the composition may further comprise additional materials, such as antimicrobials or preservatives.
- In the meantime, it is known that an active ingredient may be used simultaneously with the composition as long as it does not have any adverse effects on the pharmaceutical activity of the composition disclosed herein. For example, ceramide moisturizers are commonly used as conventional agents for atopic dermatitis, or liquid ingredients such as hydrocortisone steroids, vitamin A derivatives such as vitamin A palmitate and/or tocopherol, etc. may be used with the composition.
- When the pharmaceutical composition is used as an external preparation, an appropriate external skin preparation may be used as a base material, and an aqueous solution, a non-aqueous solvent, a suspension, an emulsion or a lyophilized preparation, etc., may be used and sterilized according to known methods.
- In practical use of the provided or administered composition disclosed herein, the dosage may be determined depending on various factors such as the route of administration, the age, sex, and weight of the patient, the severity of the disease, and the type of medicament as the active ingredient.
- In the case where the composition may be a food or a cosmetic composition, the composition may be prepared by appropriate addition of at least one food supplement or a cosmetically acceptable carrier.
- The food composition can be used in or added to, for example, healthy foods. As used herein, the term "healthy food" refers to a food product containing the composition of the present disclosure that has an enhanced function as compared to general food products. Healthy foods can be prepared by adding a general food to the composition or by encapsulation, pulverization or suspension liquefaction.
- The cosmetic composition may be added alone or together with other cosmetic ingredients, or may be appropriately used according to other known methods. Cosmetics include aftershaves, lotions, creams, facial masks and color makeups.
- Cosmetic compositions can be formulated into various forms of compositions, such as gels, creams, ointments, etc. The compositions in the form of gels, creams and ointments may be appropriately prepared according to the form of the composition by using known methods, and by addition of known softeners, emulsifiers and thickeners or other materials known in the art.
- The gel-form composition can be prepared, for example, by addition of a softener such as trimethylolpropane, polyethylene glycol and glycerol, for example, a solvent of propylene glycol, ethanol and isocetyl alcohol, and pure water.
- The preparation of the compositions in the form of creams can be carried out, for example, by addition of fatty alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, resveratrol, isostearyl alcohol and isocetyl alcohol; emulsifiers such as lipids, such as lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidyl serine, phosphoinositide and derivatives thereof, glyceryl stearate, sorbitol palmitate, sorbitol stearate, etc; natural fats and oils such as avocado oil, almond oil, babassu oil, borage oil, camellia oil, etc; lipid compositions such as ceramides, cholesterol, fatty acids, phytosphingosine, lecithin, etc; solvents, such as propylene glycol, etc; and pure water.
- The preparation of the compositions in the form of ointments can be carried out, for example, by addition of emollients, emulsifiers and waxes, for example microcrystalline wax, paraffin, ceresin, beeswax, spermaceti, petrolatum, etc.
- The composition disclosed herein may be used to prepare a medicament for treating or alleviating atopic dermatitis. As used herein, the term "treating or alleviating" means that when a patient uses a medicament, it stops or delays the course or symptoms of the disease.
-
-
Figure 1 : changes in body weight of the mice in each group. -
Figure 2 : changes in ear thickness of the mice in each group. -
Figure 3 : changes in ear weight of the mice in each group. -
Figure 4 : photos of the mice ears of each group -
Figure 5 : tissue slices of the mice ears of each group. -
Figure 6 : HPLC spectrum of the alcohol extract of mangosteen rind. - Mangosteen rind was collected and dried to 50% to 95%, extracted with a solvent (such as water or 10% to 95% alcohol), and concentrated to obtain an extract of mangosteen rind.
- The outer rind and inner rind of the mangosteen rind were separated, the outer rind of the mangosteen rind and the inner rind of the mangosteen rind were respectively dried to 50% to 95%, and extracted with a solvent (such as water or 10% to 95% alcohol), then concentrated to obtain an extract of mangosteen outer rind and an extract of mangosteen inner rind.
- Different concentrations of pastes or ointments were prepared from the mangosteen rind alcohol and water extract, the mangosteen inner rind, outer rind alcohol and water extract.
- The animals used in the experiments were 8-week-old BALB/c mice (purchased from LESCO Biotech), the body weight were 25 to 28 g and were quarantined by veterinarians for one week before entering the breeding room. The animals were divided into 9 groups, 3 in each group, a total of 27 mices. The temperature of the breeding room was set at 21 ± 2 °C, the humidity was set at 30 to 70%, and the environment was set for 12/12 hour light-dark cycle with unlimited supply of food and water.
- In the animal experiments, 2-chloro-1,3,5-trinitrobezene (TNCB) was used to induce atopic dermatitis in mice and acetone was used as the solvent to prepare 1% of TNCB which was applied to mice ears (once every 2 days, the volume was 4 ml/kg) one week prior to testings. The test substance (once per day) was started after one week, the given volume was 4 ml/kg, and the mice were continuously induced with TNCB (once every 2 days). In addition, for those groups that were simultaneously provided with test ointments and test oral substances, the oral dose was 60 mg/kg and the volume was 10 ml/kg. When TNCB and the test substance were given on the same day, in order to reduce the effect of interactions between each other, TNCB and test substance were given at least 1 hour apart. The designed experimental groups are shown in the following table. The mangosteen paste of 0.5%, 1%, 2%, 3%, 5% respectively contained 20 mg/kg, 40 mg/kg, 80 mg/kg, 120 mg/kg and 200 mg/kg of extract of mangosteen rind.
Table 1. Design of atopic dermatitis animal experiments Group TNCB induction Test substance given dose/method (daily Number of animals Normal --- solvent// topical smear 3 Vehicle control 1% TNCB solvent/ topical smear 3 1% hydrocortisone acetate/smear group (Positive control group) 1 % TNCB 1% hydrocortisone acetate/ topical smear group 3 Mangosteen paste 0.5% 1% TNCB Mangosteen paste 0.5% / topical smear 3 Mangosteen paste 1%1% TNCB Mangosteen paste 1% / topical smear 3 Mangosteen paste 2%1% TNCB Mangosteen paste 2% / topical smear 3 Mangosteen paste 3%1% TNCB Mangosteen paste 3% / topical smear 3 Mangosteen paste 5%1% TNCB Mangosteen paste 5% / topical smear 3 Mangosteen paste 2% +PO 60 mg/kg 1% TNCB Mangosteen paste 2% /topical smear + 60 mg/kg oral 3 - Changes in body weight and ear thickness of the mice were monitored twice weekly. Blood of all experimental animals were collected before TNCB induction, after the induction and before the test substance was given and when being sacrificed. After the blood was centrifuged at 3000 rpm for 30 minutes at 4 °C, serum samples were obtained and stored.
- All animals were sacrificed at the end of the third week after the test substance was given. Mice ears were removed, photographed and stored in 10% of formalin solution for histopathological observation. HE staining was used for the pathological observation (conducted by the National Laboratory Animal Center).
- Data are expressed as means ± standard deviation (SEM) and Student's t-test was used to compare the differences among treatment groups. Asterisks indicate significant differences, *p <0.05; **p <0.01; ***p <0.001.
- Body weight: After the formation of atopic dermatitis was induced by TNCB in the mice and one week after the test substance was given to the mice, only slight weight loss as a result of discomfort was observed and there was no statistically significant difference in body weight (
Figure 1 ). - Changes in ear thickness: After atopic dermatitis had been induced, various doses of test ointments were administered to the mice, a decrease in the degree of swelling (thickness) of the mice ears was observed as the dose of the test substance was increased, and when the group receiving a positive control group drug (1% Hydrocortisone acetate) and the group receiving high-dose of test substance (5%) were compared with the model group, 52.7% and 47.3% of inhibition rate (p <0.01) were observed, respectively (Table 2,
Figure 2 ).Table 2. Inhibition rate (%) of ear thickness and ear weight in experimental groups Pathological slice average inflammation degree Vehicle control group 1% Hydrocortisone Acetate Mangosteen paste (0.5%) Mangosteen paste (1%) Mangosteen paste (2%) Mangosteen paste (3%) Mangosteen paste (5%) Mangosteen paste (2%) + PO 60 mg/kg4.67± 0.47 3±0 4.67±0.47 5±0 4.67±0.47 4.33±0.94 2.67±0.47 5±0 - Changes in ear weight after sacrifice: Mice ears were removed after the experiment and weighed. It was observed that as the dose of the test substance increased, the weight of the mice ears gradually decreased. The inhibition rate of 82.4% and 69.5% (p <0.01) were respectively observed in the groups that received a positive control group drug (1% hydrocortisone acetate) and a high dose of test substance (5%) as compared with the model group. In addition, the inhibition rate of 28.2% and 28.9% were respectively observed in 2% and 3% of the test substances (p <0.05) (Table 2,
Figure 3 ). - Ear appearance after being sacrificed: Mice ears were removed for observation of the appearance at the end of 1 experiment, an intact ear contour was found in the group that received a positive control group drug (1% hydrocortisone acetate) and in the group that received a high dose (5%), less surface furfures and roughness were also observed (
Figure 4 ). - Histopathological analysis: The severity of TNCB-induced chronic-active dermatitis was divided into five levels according to the results of the pathological analysis conducted by the National Laboratory Animal Center: minimal (Grade 1), mild (Grade 2), moderate (Grade 3), moderately severe (Grade 4), and extremely severe (Grade 5). The results showed that the average severity of the pathological changes of the vehicle control group, 0.5% group and 2% group was Grade 4.67; the average severity of the pathological changes of the 1% group and 2% +
PO 60 mg/kg group wasGrade 5; the average severity of the pathological changes of the 3% group was grade 4.33; the average severity of the pathological changes of the positive control drug group (1% hydrocortisone acetate) wasGrade 3, and the average severity of the pathological changes of the 5% group was Grade 2.67 (Table 3,Figure 5 ).Table 3. Histopathological evaluation of mice ears of experimental groups Inhibition rate 1% 1% Hydrocortisone Acetate Mangosteen paste (0.5%) Mangosteen paste (1%) Mangosteen paste (2%) Mangosteen paste (3%) Mangosteen paste (5%) Mangosteen paste (2%)+ PO 60 mg/kgEar weight 82.4 16.1 0.8 28.2 28.9 69.5 37.8 Ear thickness 52.7 5.3 15.2 26.3 36.2 47.3 -1.6 - Mangosteen inner rind and outer ring extract analysis: According to the results of pathological slices conducted by the National Laboratory Animal Center, the severity of TNCB-induced chronic-active dermatitis was divided into five levels: minimal (Grade 1), mild (Grade 2), moderate (Grade 3), moderately Severe (Grade 4), and extremely severe (Grade 5). The results showed that the outer rind had an effect better than the inner rind (Table 4).
Table 4. Ear thickness and ear weight inhibition rate (%) of experimental groups Inhibition rate (%) 1% Hydrocortisone Acetate Mangosteen outer rind (4%) Mangosteen inner rind (4%) Ear weight 68.91 54.62 36.047 Ear thickness 50.75 40.04 24.84 - Serum was retained when the mice were sacrificed, and biochemical markers (IL-1β, IL-2, IL-4, IL-3, IL-5, IL-7, IL-10, IL-12 (p40), IL-15, IL-17, MCP-1, RANTES, TNF-α) in the serum were analyzed by using the MAGPIX System (Millipore, USA) and the MCYTOMAG Assay Kit (Millipore, USA).
- In the atopic dermatitis model, there was a significant increase of IL-7, IL-10, IL-15 and MCP-1, and the mangosteen rind extract was able to inhibit the increase of these markers. The inhibition rates by the mangosteen outer rind extract were 111.7%, 77.1%, 100%, 24%, 16.1%, respectively. The inhibition rates by the mangosteen inner rind extract were 97.0%, 92.8%, 65.6%, 82.7% and 27%, respectively. The results showed that mangosteen rind suppressed atopic dermatitis by inhibition of the immunomodulatory hormones rather than inhibition of pro-inflammatory cytokines IL-1 or TNF-α. Similar to the mode of action of steroid drugs, a part of the immune system could be suppressed, which in turns affected atopic dermatitis. With regard to IL-10, the mangosteen outer rind extract, which completely inhibited IL-10, was significantly superior to the inner rind extract, and IL-10 was an important cytokine formed by the
T H2 pathway antibodies. Therefore, mangosteen outer rind extract imposed more significant effects on atopic dermatitis than the mangosteen inner rind extract did. In addition, although the mode of action of mangosteen rind was similar to that of a steroid drug, with regard to IL-15, the steroids were able to inhibit the production of IL-15, but the mangosteen outer rind had more significant effect. The evidence showed that the effect of mangosteen outer rind extract was more specific than that of the steroids and did not act on the entire immune system. Accordingly, the composition and the action mechanism of the mangosteen outer rind extract were not exactly the same as those of the mangosteen inner rind extract.Table 5. Inhibition rate of various markers in serum IL-7 IL-10 IL-15 MCP-1 extract of mangosteen outer rind 77.1% 100% 24% 16.1% extract of mangosteen inner rind 92.8% 65.6% 82.7% 27% Steroid 62.7% 88% 125.1% 32.1% - The results of above examples showed that the composition of the present invention had a significant effect on atopic dermatitis.
- The chemical fingerprints spectrum of the alcohol extract of mangosteen rind was analyzed by using a high performance liquid chromatography (HPLC). 300 mg ± 1 mg of alcohol extract of mangosteen rind was weighed and placed in a 100 mL volumetric flask and diluted to 100 mL with a diluent, which was shaked by ultrasonic waves for at least 60 min until completely dissolved, allowed to stand at room temperature. After the temperature was raised and the oil-like material at the bottom was shaken and homogenized, 2 mL of solution was removed from the 100 mL flask and transferred to a 20 mL volumetric flask, after the volume was fixed with a diluent to 20 mL, a 0.45 µm of PVDF membrane was used for filtration.
- An AGILENT/1100 series high performance liquid chromatography (HPLC) system equipped with a PDA detector and an autosampler was used to perform high performance liquid chromatographical analysis. The temperature of the column (COSMOSIL MS-II, 5um, 4.6 x 250 mm, Waters) was maintained at 30 ° C during the analysis. A 10 L sample was introduced into the HPLC system. An acetonitrile-water -0.2% phosphoric acid eluent system (ACN/H2O = 72/28 (v/v), w/0.2% H3PO4) was used to perform the chemical fingerprint analysis at a flow rate of 1.0 ml/min and the peak detection was performed at a detecting wavelength of
UV 240 nm.Figure 6 shows the HPLC chemical fingerprint spectrum analysis of the alcohol extract of mangosteen rind. The results showed that the alcohol extract of mangosteen rind had HPLC peaks with the following retention times (Table 6).Table 6. HPLC spectrum wave peaks of alcohol extract of mangosteen rind Number of wave peaks Retention time (minute) 1 5.53 2 6.22 3 12.48 4 14.24 5 16.29 6 20.04 7 24.41
Claims (9)
- A composition for use in the treatment of atopic dermatitis, wherein the composition comprises an effective amount of extract of mangosteen rind, wherein the composition is a parenteral preparation.
- The composition for use according to claim 1, wherein the extract of mangosteen rind is water extract of mangosteen rind and/or alcohol extract of mangosteen rind.
- The composition for use according to claim 1, wherein the mangosteen rind is outer rind of the mangosteen rind and/or inner rind of the mangosteen rind.
- The composition for use according to claim 1, wherein the mangosteen rind is outer rind of the mangosteen rind.
- The composition for use according to claim 1, wherein the extract of mangosteen rind comprises α-mangostin and γ-mangostin.
- The composition for use according to claim 1, wherein the composition further comprises an excipient, and ratio of the excipient is 1% to 10%.
- The composition for use according to claim 1, wherein the composition is capable of inhibiting an increase of IL-7, IL-10, IL-15 or MCP-1.
- The composition for use according to claim 1, wherein the parenteral preparation is an external preparation.
- The composition for use according to claim 1, wherein the effective amount is 20 mg/kg to 200 mg/kg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL16829794T PL3326637T3 (en) | 2015-07-24 | 2016-07-21 | Use of mangosteen rind extract in preparation of medicine for treating skin diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510441951.7A CN106361784B (en) | 2015-07-24 | 2015-07-24 | Use of mangosteen fruit shell extract for treating skin diseases |
PCT/CN2016/090780 WO2017016428A1 (en) | 2015-07-24 | 2016-07-21 | Use of mangosteen rind extract in preparation of medicine for treating skin diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3326637A1 EP3326637A1 (en) | 2018-05-30 |
EP3326637A4 EP3326637A4 (en) | 2019-01-23 |
EP3326637B1 true EP3326637B1 (en) | 2021-04-07 |
Family
ID=57880548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16829794.3A Active EP3326637B1 (en) | 2015-07-24 | 2016-07-21 | Use of mangosteen rind extract in preparation of medicine for treating skin diseases |
Country Status (9)
Country | Link |
---|---|
US (1) | US10383906B2 (en) |
EP (1) | EP3326637B1 (en) |
JP (1) | JP6836581B2 (en) |
CN (1) | CN106361784B (en) |
DE (1) | DE212016000151U1 (en) |
DK (1) | DK3326637T3 (en) |
ES (1) | ES2880432T3 (en) |
PL (1) | PL3326637T3 (en) |
WO (1) | WO2017016428A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021066754A1 (en) * | 2019-10-04 | 2021-04-08 | Tipsurat Co., Ltd. | Composition of durian and mangosteen extracts and method of preparation thereof |
WO2022213665A1 (en) * | 2021-04-09 | 2022-10-13 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores |
CA3223022A1 (en) * | 2021-11-05 | 2023-05-11 | Huan-yuan CHEN | Use of mangosteen fruit shell extract in the preparation of a medicament for treating psoriasis |
EP4251185A1 (en) * | 2022-02-18 | 2023-10-04 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes |
WO2024011599A1 (en) * | 2022-07-15 | 2024-01-18 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for burn wound therapy |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3968405B2 (en) * | 1996-08-30 | 2007-08-29 | 株式会社ロッテホールディングス | Antiallergic agent |
JP2003252745A (en) * | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | MATRIX METALLOPROTEINASE (MMPs) INHIBITOR |
JP5140231B2 (en) * | 2004-04-08 | 2013-02-06 | 株式会社ロッテ | IκB kinase inhibitor |
JP2008520585A (en) * | 2004-11-16 | 2008-06-19 | ルネサンス ハーブス インコーポレイテッド | Pharmaceutical and therapeutic composition derived from Garcinia mangostana L plant |
JP2006169149A (en) * | 2004-12-15 | 2006-06-29 | Hosoda Shc:Kk | Epidermal basal cell-growth promoter of skin |
WO2007002666A2 (en) * | 2005-06-22 | 2007-01-04 | Renaissance Herbs, Inc. | Pharmaceutical and therapeutic compostions derived from garcinia mangostana l plant |
CN101428046A (en) * | 2007-11-06 | 2009-05-13 | 王莉 | Novel broad spectrum antiphlogistic pain-easing externally used medicament |
EP2301558A4 (en) * | 2008-05-22 | 2012-01-18 | Lotte Co Ltd | Preventative and/or therapeutic agent against atopic dermatitis |
JP2010018550A (en) * | 2008-07-10 | 2010-01-28 | Shinwa Sangyo Kk | Liniment for skin |
EP2391374B1 (en) * | 2009-02-02 | 2018-11-14 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
KR20120027172A (en) * | 2009-03-31 | 2012-03-21 | 가부시키가이샤 롯데 | Composition for treatment and/or prevention of dermatopathy |
JP2010195831A (en) * | 2010-06-12 | 2010-09-09 | Lotte Co Ltd | IkappaB KINASE INHIBITOR |
GB201019297D0 (en) * | 2010-11-15 | 2010-12-29 | Pitt Elaine | Improved compositions |
JP5893135B2 (en) * | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | Combinations of active substances that induce the synergistic effect of multiple targeting and their uses |
WO2014013727A1 (en) * | 2012-07-19 | 2014-01-23 | 株式会社ロッテ | Immunemodulating agent |
JP6252079B2 (en) * | 2012-10-02 | 2017-12-27 | 日本新薬株式会社 | Fibroblast growth promoter |
JP6020155B2 (en) * | 2012-12-27 | 2016-11-02 | 日本新薬株式会社 | Fibroblast growth promoter |
CN103271956A (en) * | 2013-06-18 | 2013-09-04 | 曹绍平 | Garcinia mangostana extractive, as well as preparation method and application thereof |
CN103385992B (en) * | 2013-07-23 | 2015-01-14 | 四川圣湖生物科技有限公司 | Natural herb composition used for cleaning body metabolic toxins rapidly |
JP2015042970A (en) * | 2013-07-25 | 2015-03-05 | 株式会社ファンケル | Galectin-7 production inhibitor |
CN103393576B (en) * | 2013-08-07 | 2015-12-23 | 伽蓝(集团)股份有限公司 | A kind of mangosteen extract and application thereof |
CN106535874B (en) * | 2014-07-11 | 2021-05-04 | 玫琳凯有限公司 | Pore reducing agent |
-
2015
- 2015-07-24 CN CN201510441951.7A patent/CN106361784B/en active Active
-
2016
- 2016-07-21 PL PL16829794T patent/PL3326637T3/en unknown
- 2016-07-21 EP EP16829794.3A patent/EP3326637B1/en active Active
- 2016-07-21 WO PCT/CN2016/090780 patent/WO2017016428A1/en active Application Filing
- 2016-07-21 ES ES16829794T patent/ES2880432T3/en active Active
- 2016-07-21 DK DK16829794.3T patent/DK3326637T3/en active
- 2016-07-21 DE DE212016000151.5U patent/DE212016000151U1/en active Active
- 2016-07-21 US US15/743,662 patent/US10383906B2/en active Active
- 2016-07-21 JP JP2018502248A patent/JP6836581B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
JP2018520193A (en) | 2018-07-26 |
WO2017016428A1 (en) | 2017-02-02 |
JP6836581B2 (en) | 2021-03-03 |
DE212016000151U1 (en) | 2018-03-07 |
US20180200318A1 (en) | 2018-07-19 |
PL3326637T3 (en) | 2021-10-25 |
DK3326637T3 (en) | 2021-07-05 |
CN106361784B (en) | 2020-08-14 |
EP3326637A1 (en) | 2018-05-30 |
US10383906B2 (en) | 2019-08-20 |
EP3326637A4 (en) | 2019-01-23 |
ES2880432T3 (en) | 2021-11-24 |
CN106361784A (en) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3326637B1 (en) | Use of mangosteen rind extract in preparation of medicine for treating skin diseases | |
TWI627960B (en) | Use of extract of mangosteen rind for treating dermatological diseases | |
WO2011093469A1 (en) | Expression promoter for redox-related factor | |
JP2018513204A (en) | Compositions and methods for neuroprotection and treatment of neurodegeneration | |
EP2992879B1 (en) | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof | |
US20240197803A1 (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for treating psoriasis | |
CN117159626A (en) | Composition of caffeoylspermidine compound, use thereof and spermidine supplement thereof | |
KR101708761B1 (en) | Composition for preventing or treating atopic dermatitis comprising purine derivative or its salt | |
TWI788228B (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores | |
KR102412656B1 (en) | Composition for preventing or treating of atopic dermatitis comprising chamaejasmine | |
CN112402411B (en) | Application of chalcone compound in preparation of sleep improvement medicine | |
WO2023155158A1 (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes | |
US20230248795A1 (en) | Kava compositions and methods of making same | |
WO2024011599A1 (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for burn wound therapy | |
CN117298164A (en) | Application of mangosteen shell extract in preparing medicine for treating bedsores | |
JPS5913707A (en) | Cosmetic composition containing adzuki saponin | |
JPS638328A (en) | Remedy for liver disease | |
KR20240044381A (en) | Modified release formulations containing withanolide | |
TW202319063A (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for treating psoriasis | |
KR20110105115A (en) | Pharmaceutical composition for preventing or treating atopic dermatitis containing the membrane-separated extracts of platycodon grandiflorum or platycoside e as an active ingredient | |
CN117304054A (en) | Enrichment method of caffeoylspermidine compound, anti-aging property and method for inhibiting histone deacetylase | |
JP3494845B2 (en) | Allergic disease prevention / treatment agent | |
US20170369414A1 (en) | O-Quinone Compounds as Agents Neutralising Nitric Oxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180220 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/38 20060101AFI20181213BHEP Ipc: A61P 37/08 20060101ALI20181213BHEP Ipc: A61P 17/00 20060101ALI20181213BHEP Ipc: A61P 17/04 20060101ALI20181213BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181221 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200416 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/08 20060101ALI20201005BHEP Ipc: A61K 36/38 20060101AFI20201005BHEP Ipc: A61P 17/04 20060101ALI20201005BHEP Ipc: A61P 17/00 20060101ALI20201005BHEP |
|
INTG | Intention to grant announced |
Effective date: 20201021 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1378790 Country of ref document: AT Kind code of ref document: T Effective date: 20210415 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016055788 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210702 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2880432 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210809 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210708 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210807 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016055788 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210807 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210721 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160721 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1378790 Country of ref document: AT Kind code of ref document: T Effective date: 20210407 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20230619 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230720 Year of fee payment: 8 Ref country code: IT Payment date: 20230731 Year of fee payment: 8 Ref country code: IE Payment date: 20230726 Year of fee payment: 8 Ref country code: GB Payment date: 20230724 Year of fee payment: 8 Ref country code: ES Payment date: 20230821 Year of fee payment: 8 Ref country code: AT Payment date: 20230718 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230724 Year of fee payment: 8 Ref country code: FR Payment date: 20230724 Year of fee payment: 8 Ref country code: DK Payment date: 20230724 Year of fee payment: 8 Ref country code: DE Payment date: 20230717 Year of fee payment: 8 Ref country code: BE Payment date: 20230719 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20231019 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20240626 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240722 Year of fee payment: 9 |